AbbVie to buy Gilgamesh drug candidate in $1.2B deal

AbbVie is buying a depression drug candidate from next-generation psychedelics developer Gilgamesh Pharmaceuticals, in a deal worth up to $1.2 billion.

Why it matters: The deal could lend legitimacy to controversial psychedelic therapies.